-
公开(公告)号:EP4452997A1
公开(公告)日:2024-10-30
申请号:EP22912469.8
申请日:2022-12-22
IPC分类号: C07K1/107 , C07K1/13 , C07D249/04 , C01B21/08 , C07C2/38 , C07D499/40 , A61K47/68
-
72.
公开(公告)号:EP4452410A1
公开(公告)日:2024-10-30
申请号:EP22850890.9
申请日:2022-12-21
-
公开(公告)号:EP4452320A1
公开(公告)日:2024-10-30
申请号:EP22854694.1
申请日:2022-12-21
申请人: GENENTECH, INC.
-
公开(公告)号:EP4452314A1
公开(公告)日:2024-10-30
申请号:EP22839882.2
申请日:2022-12-21
发明人: HYDE, Stephen , MIAH, Kamran , GILL, Deborah , DY, Yue
IPC分类号: A61K39/215 , C07K14/165
-
公开(公告)号:EP4452298A2
公开(公告)日:2024-10-30
申请号:EP22912464.9
申请日:2022-12-22
申请人: Memorial Sloan-Kettering Cancer Center , Sloan-Kettering Institute for Cancer Research , Memorial Hospital for Cancer and Allied Diseases
IPC分类号: A61K38/17 , A61P37/02 , A61K39/395 , C07K19/00 , A61P35/00
-
公开(公告)号:EP4452295A1
公开(公告)日:2024-10-30
申请号:EP22912102.5
申请日:2022-12-20
申请人: Virenc AB
发明人: KHALAF, Hazem , BENGTSSON, Torbjörn , HINKULA, Jorma , MELIK, Wessam , SELEGÅRD, Robert , AILI, Daniel
IPC分类号: A61K38/16 , A61P31/12 , C07K14/335
-
公开(公告)号:EP4452294A1
公开(公告)日:2024-10-30
申请号:EP22826571.6
申请日:2023-04-21
-
公开(公告)号:EP4451863A1
公开(公告)日:2024-10-30
申请号:EP22851345.3
申请日:2022-12-16
IPC分类号: A01K67/027 , C07K14/705 , C12N9/48
-
公开(公告)号:EP4428147A3
公开(公告)日:2024-10-30
申请号:EP24177118.7
申请日:2018-11-09
摘要: The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, fracture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.
-
公开(公告)号:EP4414704A3
公开(公告)日:2024-10-30
申请号:EP24166021.6
申请日:2018-06-08
IPC分类号: C07K14/74 , C12N5/10 , C12N15/10 , C12Q1/02 , C12Q1/68 , C40B20/04 , C12N5/0783 , C12N5/09 , C40B40/02 , G01N33/50 , A61K39/00
摘要: Described herein, in one aspect, are antigen presenting cells (APCs) comprising an exogenous nucleic acid encoding one or more candidate antigens, wherein the one or more candidate antigens are expressed and presented with MHC class I or MC class II molecules; a molecular reporter of Granzyme B (GzB) activity; and c) an exogenous inhibitor of caspase-activated deoxyribonuclease (CAD)-mediated DNA degradation, a CAD knockout, or a caspase knockout (e.g., caspase 3 knockout). Described herein, in another aspect, is a system for detection of recognized antigen presentation by an antigen presenting cell to a cytotoxic lymphocyte or NK cell.
-
-
-
-
-
-
-
-
-